Experts React to Study on At-Home Blood and Cognitive Tests for Alzheimer’s Risk
A new study published in Nature Communications evaluates the efficacy of at-home finger-prick blood tests combined with digital cognitive assessments for identifying Alzheimer’s disease risk. Experts from the UK Dementia Research Institute and Alzheimer’s Research UK highlight the potential of this approach to revolutionize early screening by offering a low-cost, scalable solution that improves access for those unable to visit specialist clinics. The research demonstrates that biomarkers measured via self-administered tests correlate with cognitive decline, particularly using the pTau217 marker. However, specialists caution that the technology is not yet a diagnostic tool and requires further validation across diverse populations and co-morbidities. Approximately 20% of participants needed assistance, indicating accessibility challenges. While promising for triaging patients into clinical trials or further diagnostic pathways like PET scans, experts emphasize the need for larger studies and increased healthcare capacity to handle potential referrals. The consensus is that while the method shows high sensitivity and proof of principle, it remains in early stages and is not recommended for routine clinical use until robustness and accuracy are confirmed in real-world settings.
Wire timeline
Experts React to Study on At-Home Blood and Cognitive Tests for Alzheimer’s Risk
A new study published in Nature Communications evaluates the efficacy of at-home finger-prick blood tests combined with digital cognitive assessments for identifying Alzheimer’s disease risk. Experts from the UK Dementia Research Institute and Alzheimer’s Research UK highlight the potential of this approach to revolutionize early screening by offering a low-cost, scalable solution that improves access for those unable to visit specialist clinics. The research demonstrates that biomarkers measured via self-administered tests correlate with cognitive decline, particularly using the pTau217 marker. However, specialists caution that the technology is not yet a diagnostic tool and requires further validation across diverse populations and co-morbidities. Approximately 20% of participants needed assistance, indicating accessibility challenges. While promising for triaging patients into clinical trials or further diagnostic pathways like PET scans, experts emphasize the need for larger studies and increased healthcare capacity to handle potential referrals. The consensus is that while the method shows high sensitivity and proof of principle, it remains in early stages and is not recommended for routine clinical use until robustness and accuracy are confirmed in real-world settings.
Science Media Centre